Nesina is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Takeda Pharmaceuticals America, Inc.. The primary component is Alogliptin Benzoate.
Product ID | 64764-625_0780199d-23ac-4b18-8dd4-4e7b31c79dad |
NDC | 64764-625 |
Product Type | Human Prescription Drug |
Proprietary Name | Nesina |
Generic Name | Alogliptin |
Dosage Form | Tablet, Film Coated |
Route of Administration | ORAL |
Marketing Start Date | 2013-01-25 |
Marketing Category | NDA / NDA |
Application Number | NDA022271 |
Labeler Name | Takeda Pharmaceuticals America, Inc. |
Substance Name | ALOGLIPTIN BENZOATE |
Active Ingredient Strength | 6 mg/1 |
Pharm Classes | Dipeptidyl Peptidase 4 Inhibitors [MoA],Dipeptidyl Peptidase 4 Inhibitor [EPC] |
NDC Exclude Flag | N |
Listing Certified Through | 2020-12-31 |
Marketing Start Date | 2013-01-25 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA022271 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2013-01-25 |
Marketing Category | NDA |
Application Number | NDA022271 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2013-01-25 |
Ingredient | Strength |
---|---|
ALOGLIPTIN BENZOATE | 6.25 mg/1 |
SPL SET ID: | a3768c7e-aa4c-44d3-bc53-43bb7346c0b0 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI | |
UPC Code |
NDC | Brand Name | Generic Name |
---|---|---|
64764-125 | Nesina | alogliptin |
64764-250 | Nesina | alogliptin |
64764-625 | Nesina | alogliptin |
45802-087 | Alogliptin | Alogliptin |
45802-103 | Alogliptin | Alogliptin |
45802-150 | Alogliptin | Alogliptin |
50090-5574 | Alogliptin | Alogliptin |
71610-300 | Alogliptin | Alogliptin |
71610-661 | Alogliptin | Alogliptin |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
NESINA 77446275 not registered Dead/Abandoned |
Takeda Pharmaceutical Company Limited 2008-04-11 |
NESINA 77140293 3582114 Live/Registered |
Takeda Pharmaceutical Company Limited 2007-03-26 |